Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Laboratories, Inc.

http://www.frx.com

Latest From Forest Laboratories, Inc.

Sanofi Looks To Atomwise For More AI Help

Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.

Deals Artificial Intelligence

India Proposes OTC List In Draft Rule Lacking Clarity On Pricing, Switching Pathway

India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?

Prescription To OTC Switch OTC Drugs

India Proposes OTC List But Clarity On Pricing, Switching Pathway Awaited

India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?

India Prescription To OTC Switch

India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs

The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.

Commercial India
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Aptalis Pharma Inc. (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.
UsernamePublicRestriction

Register